Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial.
暂无分享,去创建一个
Akshay S. Desai | A. Desai | J. McMurray | P. Jhund | M. Vaduganathan | R. D. de Boer | S. Inzucchi | K. Docherty | J. Fang | M. Kosiborod | M. McGrath | F. Martinez | A. Langkilde | Magnus Petersson | Finnian R. Mc Causland | S. Shah | S. Solomon | A. Hernandez | S. Verma | Carolyn S P Lam | B. Claggett | James Fang | J. F. K. Saraiva | S. J. Shah | Carolyn S. P. Lam | J. Saraiva | Sanjiv J. Shah
[1] Akshay S. Desai,et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER , 2022, Nature Medicine.
[2] Akshay S. Desai,et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. , 2022, The New England journal of medicine.
[3] Akshay S. Desai,et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials , 2022, The Lancet.
[4] A. Voors,et al. Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease , 2022, Circulation.
[5] Sanjiv J. Shah,et al. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial. , 2022, JACC. Heart failure.
[6] S. Solomon,et al. Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF , 2022, European journal of heart failure.
[7] M. Pfeffer,et al. Angiotensin–neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure , 2022, European journal of heart failure.
[8] G. Filippatos,et al. Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial , 2021, European journal of heart failure.
[9] G. Filippatos,et al. Empagliflozin and Major Renal Outcomes in Heart Failure. , 2021, New England Journal of Medicine.
[10] P. Ponikowski,et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.
[11] J. McMurray,et al. Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.
[12] Akshay S. Desai,et al. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction , 2020, Circulation.
[13] S. Solomon,et al. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction , 2020, Circulation.
[14] Akshay S. Desai,et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. , 2019, The New England journal of medicine.
[15] J. Coresh,et al. Performance of GFR Slope as a Surrogate Endpoint for Kidney Disease Progression in Clinical Trials: A Statistical Simulation. , 2019, Journal of the American Society of Nephrology : JASN.
[16] B. Zinman,et al. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. , 2018, Journal of the American Society of Nephrology : JASN.
[17] S. Solomon,et al. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. , 2018, The lancet. Diabetes & endocrinology.
[18] S. Solomon,et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM‐study programme , 2016, European journal of heart failure.
[19] A. Cheung,et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[20] R. McKelvie,et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. , 2014, Journal of the American College of Cardiology.
[21] Sanjiv J Shah,et al. Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.
[22] C. O'connor,et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. , 2014, European heart journal.
[23] Nish Chaturvedi,et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.
[24] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[25] Susan Anderson,et al. Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.
[26] H. Tsutsui. [Candesartan in heart failure: assessment of reduction in mortality and morbidity]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.
[27] N. Freemantle,et al. FASTTRACK : The perindopril in elderly people with chronic heart failure (PEP-CHF) study , 2006 .
[28] A. Go,et al. Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study , 2006, Circulation.
[29] Hans L. Hillege,et al. Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure , 2006, Circulation.
[30] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.
[31] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[32] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[33] N. Freemantle,et al. Perindopril for elderly people with chronic heart failure: the PEP‐CHF study , 1999, European heart journal.
[34] J. Coresh,et al. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[35] Akshay S. Desai,et al. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. , 2019, JACC. Heart failure.